AARTIPHARM

Aarti Pharmalabs Share Price

₹629.45 -32.6 (-4.92%)

22 Jan, 2025 12:32

SIP TrendupStart SIP in AARTIPHARM

Start SIP

Performance

  • Low
  • ₹628
  • High
  • ₹664
  • 52 Week Low
  • ₹400
  • 52 Week High
  • ₹722
  • Open Price₹662
  • Previous Close₹662
  • Volume221,616

Investment Returns

  • Over 1 Month + 10.25%
  • Over 3 Month + 4.65%
  • Over 6 Month + 8.95%
  • Over 1 Year + 20.03%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarti Pharmalabs for Steady Growth!

Invest Now

Aarti Pharmalabs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25
  • PEG Ratio
  • -1.1
  • Market Cap Cr
  • 5,705
  • P/B Ratio
  • 3.1
  • Average True Range
  • 27.88
  • EPS
  • 25.17
  • Dividend Yield
  • 0.5
  • MACD Signal
  • 9.52
  • RSI
  • 53.36
  • MFI
  • 44.42

Aarti Pharmalabs Financials

Aarti Pharmalabs Technicals

EMA & SMA

Current Price
₹629.45
-32.6 (-4.92%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹655.58
  • 50 Day
  • ₹643.89
  • 100 Day
  • ₹632.90
  • 200 Day
  • ₹600.94

Resistance and Support

669.88 Pivot Speed
  • R3 707.37
  • R2 697.48
  • R1 679.77
  • S1 652.17
  • S2 642.28
  • S3 624.57

What's your outlook on Aarti Pharmalabs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarti Pharmalabs Ltd. is a leading pharmaceutical company in India, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. It caters to global markets, providing high-quality and innovative solutions for various therapeutic segments.

Aarti Pharmalabs has an operating revenue of Rs. 1,967.98 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 16% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 11% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 24 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarti Pharmalabs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-05 Quarterly Results
2024-05-13 Audited Results & Final Dividend
2024-02-07 Quarterly Results & Interim Dividend
2023-11-07 Quarterly Results
Date Purpose Remarks
2024-07-31 FINAL Rs.1.00 per share(20%)Final Dividend
2024-02-19 INTERIM Rs.2.00 per share(40%)Interim Dividend
View More

Aarti Pharmalabs F&O

Aarti Pharmalabs Shareholding Pattern

44.66%
3.93%
6.09%
8.64%
0%
30.39%
6.29%

About Aarti Pharmalabs

  • NSE Symbol
  • AARTIPHARM
  • BSE Symbol
  • 543748
  • Managing Director
  • Mr. Narendra J Salvi
  • ISIN
  • INE0LRU01027

Similar Stocks to Aarti Pharmalabs

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹629 As on 22 January, 2025 | 12:18

The Market Cap of Aarti Pharmalabs is ₹5704.5 Cr As on 22 January, 2025 | 12:18

The P/E ratio of Aarti Pharmalabs is 25 As on 22 January, 2025 | 12:18

The PB ratio of Aarti Pharmalabs is 3.1 As on 22 January, 2025 | 12:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23